TSXV:DVA

Proprietary  Transdermal  Delivery  Platform  for  

Targeted  Therapeutics

1Investor  Presentation  September  2017 TSXV:DVA

TSXV:DVA

Forward  Looking  Statements

This presentation is not, and under no circumstances is to be construed as, a prospectus, offering memorandum, oradvertisement or offering of securities. This presentation is for the confidential use of only those persons to whom it istransmitted or provided by Delivra. By their acceptance of this presentation, recipients agree that they will not transmit,reproduce or make available to any person, other than their professional advisors, this presentation or any of theinformation contained herein.

Certain information included in this presentation, including any information as to future financial or operating performanceand other statements that express expectations or estimates of future performance, constitute 'forward-­lookingstatements'. For example, statements about expected market growth, future revenues and profits, product development,product performance, expected timing and receipt of regulatory product approvals and patents, operating costs, andindustry conditions, are all forward-­looking statements. Forward-­looking statements are necessarily based upon a numberof estimates and assumptions that, while considered reasonable by management, are inherently subject to significantbusiness, economic and competitive uncertainties and contingencies. Forward-­looking statements involve known andunknown risks, uncertainties and other factors that may cause actual financial results, performance or achievements to bematerially different from the estimated future results, performance or achievements expressed or implied by thoseforward-­looking statements, and the forward-­looking statements are not guarantees of future performance. Except asrequired by law, Delivra disclaims any obligation to update or revise any forward-­looking statements, whether as a resultof new information, events or otherwise.

Readers are cautioned not to put undue reliance on these forward-­looking statements, and not to use this document astheir sole source for decision making. Readers are encouraged to seek additional information and independent advice.This presentation contains information obtained by Delivra from third parties, including but not limited to market data. TheCompany believes such information to be accurate but has not independently verified such information. To the extentsuch information obtained from third party sources, there is a risk that the assumptions made and conclusions drawn byDelivra based on such representations are not accurate.

2

TSXV:DVA

OUR  FOCUS  IS  TOdevelop  new  treatments  using  our  unique,  proprietary  delivery  platform  to  address  unmet  patient  needs

3

TSXV:DVA

Using  our  innovative  delivery  technology  to  

addressmulti-­billion  dollar  unmet  

medical  needs

Built  a  portfolio  of  consumer  products  and    prescription  productsto  deliver  topical  treatments

Deliver  immediate  growth  with  a  portfolio  of  commercialized  natural  

OTC  products+$5  million  in  revenue

Making  Existing  Drugs  Work  More  Effectively

4

TSXV:DVA

The  Benefit  of  Transdermal  Therapeutics

5

Pills Plant-­based

DO  NOT  DELIVER  drugs  to  a  specific  area

DO  NOT  SURVIVE  the  GI  tract  well

FAST-­ACTING

TARGETS  SPECIFIC  AREAS

IMPROVED  EFFICACY

SUSTAINED  RELEASE

SAFE  &  STABLE

TOPICAL  CREAM  BASE

TSXV:DVA

Our  Value  Proposition  

6

Use  our  innovative  transdermal  delivery  

platform  for  the  novel  and  improved  use  of  consumer  and  prescription  products  

Pharmaceutical  Portfolio• Pain  management,  sleep,  anxiety• Diabetic  ulcers• Scleroderma

OTC  Portfolio• Pain  management• Nerve  Pain• Varicose• Wound  Healing  

1

2

TSXV:DVA

Pharmaceutical  Portfolio  

7

• Doxycycline  is  a  50  year-­old  drug,  globally  accepted,  but  is  very  unstable,  oxidizes  rapidly

• prLIV-­DOX  overcomes  Doxy’s  inherent  instability  and  demonstrates  efficacy  

• Distributed  and  promoted  through  compounded  pharmacy  since  February  2017

• Currently  covered  by  private  insurers  

• Near-­term  revenue  with  90%  margins

Diabetic-­wound  healing  

• Advanced    topical  formulation  of  Celebrex™  (celecoxib)

• Improved  safety  and  efficacy  profile  

• Reduced  harmful  side  effects  (cardiovascular  and  gut  upset),  as  a  result  of  oral  delivery  issues  associated  with  metabolism  in  the  gastrointestinal  tract

• Opens  new  market  opportunity  

• Driving  prescription  sales  through  compound  pharmacy  

Inflammatory  Diseases    

• Signed  exclusive  licensing  deals  to  co-­develop  a  portfolio  of  pharmaceutical-­grade  medical  products  in  a  mono-­dose  format

• Health-­Canada  approved  GMP-­contract  manufacturing  facility  for  QA/QC  testing

• Agreement  provides  Delivra  with  double-­digit  royalties  and  initial  cash  payments

• Extended  to  develop  Hemp,  Terpene  and  Flavonoid  products  

Cannabis-­based  therapeutics  

TSXV:DVA

Cannabis-­based  Therapies:  Market  Needs  Quality  Control

8

Regulation  and  legalization  will  significantly  increase  requirements  for  product  safety,  consistency  and  accurate  dosing  

Stringent  regulations  will  require  manufactures  to  adhere  to  strict  QA/QC  guidelines  under  GMP  environments  

Development  of  new  formulations  for  specific  medical  conditions  

Our  technology  delivers  consistent,  safe  and  precise  dosing

SleepMoodAnxiety  StressPain  

TSXV:DVA

prLiv-­Dox  for  Diabetic  Wound  Care

9

Wounds  International,  2013  – DFU  (Diabetic  Foot  Ulcer)  DPN  (Diabetic  Peripheral  Neuropathy)

0

20

40

60

80

100

120

34%

37%

29%

prLiv-­DOX250  patients  treated  

Healed  Ulcer Improved No  ChangeDiabetes  affects  3.5  Million  Canadians  

TSXV:DVA

OTC  Portfolio  of  Cash-­flowing  Natural  Products

10

Also  available  in  natural  health  stores,  independent  pharmacies,  and  professional  clinics.

#1  selling  natural  pain  relief

#1  selling  natural  nerve-­pain  reliefin  Canada  

+$5  Million  in  Revenue  

Deep  national  distribution  

TSXV:DVA

Delivered  Strong  Year  over  Year  Growth  

• Increased  2016  revenue  by  30%  to  $3.8M  for  consumer  products

• Q2  72%  gross  margin  

• Significantly  reduced  1H  operating  costs,  strengthening  cash  flow  

• Grew  market  share  in  most  important  portfolio

11

0

200,000

400,000

600,000

800,000

1,000,000

1,200,000

1,400,000

Q2  2016 Q3  2016 Q4  2016 Q1  2017 Q2  2017

Revenue Gross  profit

TSXV:DVA

12-­Month  Catalysts

Consumer  Portfolio• Grow  sales  through  efficient  marketing  investment  enabling  greater  efficiency  and  return  by  focusing  on  more  dense  geographies

• Achieve  OTC  positive  EBITDA  

12

Pharmaceutical  Portfolio• Launch  a  suite  of  medical  cannabis-­based  therapeutics  targeting  pain  management  under  a  third-­party  label  

• Drive  early  support  of  Liv-­DOX  with  specialists  through  compound  pharmacy  sales  and  drive  a  clear  path  to  reimbursement

TSXV:DVA

Proprietary  Transdermal  Delivery  Platform  for  

Targeted  Therapeutics

13Investor  Presentation  September  2017 TSXV:DVA